Effect of vitamin E in nonalcoholic fatty liver disease with metabolic syndrome: A propensity score-matched cohort study.
10.3350/cmh.2015.21.4.379
- Author:
Gi Hyun KIM
1
;
Jung Wha CHUNG
;
Jong Ho LEE
;
Kyeong Sam OK
;
Eun Sun JANG
;
Jaihwan KIM
;
Cheol Min SHIN
;
Young Soo PARK
;
Jin Hyeok HWANG
;
Sook Hyang JEONG
;
Nayoung KIM
;
Dong Ho LEE
;
Jin Wook KIM
Author Information
1. Department of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea. kimjw@snubh.org
- Publication Type:Clinical Trial ; Controlled Clinical Trial ; Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Nonalcoholic fatty liver disease;
Vitamin E;
Metabolic syndrome;
Propensity score
- MeSH:
Adult;
Aged;
Alanine Transaminase/blood;
Aspartate Aminotransferases/blood;
Body Weight;
Cohort Studies;
Female;
Humans;
Lipoproteins, HDL/blood;
Lipoproteins, LDL/blood;
Liver/pathology;
Male;
Metabolic Syndrome X/*complications/diagnosis/drug therapy;
Middle Aged;
Non-alcoholic Fatty Liver Disease/*complications/diagnosis/*drug therapy;
Propensity Score;
Republic of Korea;
Retrospective Studies;
Vitamin E/*therapeutic use
- From:Clinical and Molecular Hepatology
2015;21(4):379-386
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Vitamin E improves the biochemical profiles and liver histology in nonalcoholic steatohepatitis, but the role of vitamin E is not clearly defined in the management of nonalcoholic fatty liver disease (NAFLD) which includes both simple steatosis and steatohepatitis. Co-morbid metabolic syndrome increases the probability of steatohepatitis in NAFLD. In this study, we aimed to determine the short-term effects of vitamin E and off-treatment durability of response in a propensity-score matched cohort of NAFLD patients with metabolic syndrome. METHODS: A retrospective cohort was constructed by retrieving 526 consecutive NAFLD patients from the electronic medical record data warehouse of a tertiary referral hospital in South Korea. Among them, 335 patients (63.7%) had metabolic syndrome and were eligible for vitamin E therapy. In order to assess the effect of vitamin E, propensity score matching was used by matching covariates between control patients (n=250) and patients who received vitamin E (n=85). RESULTS: The PS-matched vitamin E group (n=58) and control group (n=58) exhibited similar baseline metabolic profiles. After 6 months of vitamin E therapy, the mean ALT levels decreased significantly compared to PS-matched control (P<0.01). The changes in metabolic profiles (body weight, lipid and glucose levels) did not differ between control and vitamin E groups during the study period. CONCLUSIONS: Short-term vitamin E treatment significantly reduces ALT levels in NAFLD patients with metabolic syndrome, but metabolic profiles are not affected by vitamin E.
